Nvidia CEO Jensen Huang Says AI Lets Anyone Write Code
Nvidia CEO Jensen Huang says that you don't have to be an expert programmer to prompt AI to write a program for you, making AI the "great equalizer" when it comes to bringing ideas to life with code.
In remarks on stage at London Tech Week on Monday, Huang said that the barrier to code used to be high. Programmers had to learn specific languages and figure out how to architect code efficiently.
Related: Want to Get Hired at Nvidia? This Is the Most Important Part of the Interview Process, According to CEO Jensen Huang
Now, Huang said that AI enables even non-programmers to write code using natural language. AI coding assistants like Cursor and Replit can easily take a written prompt in plain English and turn it into code. The practice of relying on these AI assistants to write a complete program is known as "vibe coding" — and even Google CEO Sundar Pichai admitted last week to "vibe coding" a webpage.
"Now, all of a sudden… there's a new programming language," Huang said at London Tech Week, per CNBC. "This new programming language is called 'human.'"
Huang noted that while relatively few people know how to work with programming languages like C++ or Python, "everybody… knows 'human'." The way to ask a computer to write a program is to "just ask it nicely," as you would a person, Huang said.
Nvidia CEO Jensen Huang at London Tech Week. Photo byAI users are already following Huang's advice. ChatGPT users are saying "please" and "thank you" to the AI chatbot, treating it as politely as they would a person. The practice has a downside, though: ChatGPT-maker OpenAI has lost tens of millions of dollars in added electricity costs to process the politeness interactions. However, OpenAI CEO Sam Altman called it "tens of millions of dollars well spent."
Related: How Nvidia CEO Jensen Huang Transformed a Graphics Card Company Into an AI Giant: 'One of the Most Remarkable Business Pivots in History'
Non-coders are already tapping into AI to create projects and web apps without manually writing a single line of code. Kevin Roose, a technology columnist for The New York Times, wrote in February that he was able to vibe code a new app called LunchBox Buddy to help him figure out what he should pack his son for lunch based on a picture of his fridge. Harvard University neuroscience student, Rishab Jain, told NBC News last month that he vibe-coded an app to translate ancient texts into English.
Nvidia is the second most valuable company in the world at the time of writing, with a market capitalization of $3.48 trillion. The AI chipmaker's stock has grown by nearly 1,500% in the past five years and over 17% this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Analysts reboot Micron Technology stock price target ahead of earnings
Analysts reboot Micron Technology stock price target ahead of earnings originally appeared on TheStreet. An elephant might never forget but Micron Technology () has more storage space. The Boise, Idaho, company makes memory and storage chips for data centers, computers and smartphones, and its client list includes such tech-sector superstars as AI-chip chieftain Nvidia () , Mac and iPhone maker Apple () , Facebook parent Meta Platforms () and software kingpin Microsoft () . 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰 Make no mistake, there's money in memories, and we're not just talking about those singing cats on Broadway. "After the historic downturn of 2022–2023, the memory industry has entered a phase of strong recovery. In 2024, memory revenue reached a record $170 billion,' according to market researcher Yole Group. "This rebound was fueled by AI-training requirements in data centers, with [high-bandwidth memory) playing a pivotal role due to its premium pricing and performance advantages," the firm added. HBM continues to outperform the broader DRAM chip segment, Yole Group said. This year HBM revenue is set to nearly double to around $34 billion. Micron is a key player in the HBM market, offering solutions like HBM3E and HBM4 designed for high-performance computing and AI applications. The company recently joined the Trump administration to unveil plans to expand its U.S. investments to about $150 billion in domestic memory manufacturing and $50 billion in research and development, creating an estimated 90,000 direct and indirect jobs. More Tech Stocks: Amazon tries to make AI great again (or maybe for the first time) Veteran portfolio manager raises eyebrows with latest Meta Platforms move Google plans major AI shift after Meta's surprising $14 billion move 'Micron's U.S. memory manufacturing and R&D plans underscore our commitment to driving innovation and strengthening the domestic semiconductor industry,' Chairman, President and CEO Sanjay Mehrotra said in a statement. The company's shares are up nearly up nearly 45% this year and off 16% from this time in 2024. Investment firms have been issuing research reports for Micron Technology ahead of its fiscal-third-quarter earnings report, scheduled for June 25. Wedbush boosted its price target on Micron to $150 from $130 while maintaining an outperform rating. The firm said memory-pricing trends turned more positive in the second quarter. And while Wedbush said it doesn't see as significant an inflection in Q3 as it had been expecting back in March, the firm said pricing for both DRAM and NAND, which are two types of semiconductor memory, "still will lift over the next couple of quarters." Better fundamentals are driven by stronger enterprise/server demand, which started around April and looks to hold through the rest of the year, Wedbush said. Demand for both AI and standard workloads appears better than might have been initially anticipated, it said. "Moreover, we view growing [high-bandwidth memory] requirements as not just positive for MU's numbers but also ultimately positive for industry dynamics as [capital spending] and clean-room space are reallocated to support HBM growth," Wedbush will limit the likelihood of too much supply of NAND/DRAM, and it increases the probability that production of more standard parts will trail demand. That, the firm said, would create a more positive pricing/margin cycle vs. what is embedded in its expectations, the firm said. Morgan Stanley maintained an equal-weight rating and $98 price target on Micron, given how much the stock has rallied already, according to The Fly. But the investment firm is "tactically bullish," given that AI spending is materially accelerating as Micron grows its participation. The investment firm, which notes that its estimates remain 20% above consensus for August-quarter earnings, also highlights Sandisk, () which it likes better long term and on which it has an overweight rating. Based in Milpitas, Calif., Sandisk designs and produces flash-memory products, including memory cards, USB flash drives and solid-state drives. Consensus numbers have started to come up for Micron over the past few weeks, but in addition to Morgan Stanley being about 20% above consensus for August earnings per share, the firm is also 14% above for November after it raised estimates six weeks reboot Micron Technology stock price target ahead of earnings first appeared on TheStreet on Jun 20, 2025 This story was originally reported by TheStreet on Jun 20, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
B.Riley Maintained a Buy Rating on Onto Innovation (ONTO), Keeps the PT
Onto Innovation Inc. (NYSE:ONTO) is one of the 11 Best Tech Stocks to Buy On the Dip. On June 13, Financial analyst Craig Ellis maintained a Buy rating on Onto Innovation Inc. (NYSE:ONTO) with a price target of $160. The rating comes after the company announced enhanced leadership with two new executive appointments. The company appointed Brian Roberts as chief financial officer and Shirley Chen as senior vice president of customer success in a move to achieve its strategic objectives. On May 8, Onto Innovation Inc. (NYSE:ONTO) reported its Q1 2025 results, highlighting record quarterly revenue of $267 million, marking the seventh consecutive quarter of growth. The growth was driven by growth in advanced nodes and advanced packaging markets, particularly supporting AI compute engines and increased investments in cloud and enterprise servers. A technician observing a macro defect inspection process, the precision of the company's systems. Nearly all the products of Onto Innovation Inc. (NYSE:ONTO) are manufactured in the United States, which exposes the company to higher incoming costs due to tariffs imposed by the Trump administration. Management noted accelerating strategic programs to establish manufacturing capabilities in Asia to help eradicate the tariff threat. The company expects shipments from these new facilities to begin in the second half of 2025, thereby further improving its margins. Onto Innovation Inc. (NYSE:ONTO) is engaged in the designing, development, and manufacturing of advanced equipment and systems for microelectronics. It focuses on key areas including Control methodology, Defect Inspection, Lithography Systems, and Data Analysis Systems. While we acknowledge the potential of ONTO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
